OBJECTIVE:To observe short-term efficacy and ADR of nedaplatin concurrent chemoradiotherapy combined with thermotherapy in the treatment of middle and advanced esophageal cancer. METHODS:64 patients with middle and advanced esophageal cancer were randomly divided into control group and treatment group,with 32 cases in each group. Control group was given nedaplatin concurrent chemoradiotherapy,nedaplatin 30 mg/m2,ivgtt,every week during chemotherapy;treatment group re-ceived thermotherapy by high frequency heating machine before chemoradiotherapy,60 min/time,twice a week;received chemora-diotherapy 30 min after thermotherapy. Short-term efficacy and ADR were observed in 2 groups. RESULTS:The short-term total effective rate of treatment group(84.4%)was higher than that of control group(62.5%),with statistical significance(P<0.05). The incidence of bone marrow suppression,radioactive esophagitis and gastrointestinal reactions in treatment group vs. control group were(21.9%)vs.(46.9%),(18.8%)vs.(56.3%),(31.3%)vs.(59.4%),with statistical significance(P<0.05). CONCLU-SIONS:Nedaplatin concurrent chemoradiotherapy combined with thermotherapy is better than concurrent chemoradiotherapy in the treatment of middle and advanced esophageal cancer with low incidence of ADR.

Objective To investigate the effect of idarubiein to imensify the MAC (IMAC) as preparative regimen for autologous peripheral blood stem cell transplantation(APBSCT)in acute myeioid leukemia.Methods Fourteen patients with acute myeloid leukemia who underwent APBSCT were analysed. IMAC was used as preparative regimens.Results All patients were engrafted successfully.The disease-free survival could be Ben in 8 cases(57.1%),the median disease-free survival duration were 26(8-72)months and no treatment-related mortality was present.Conclusion This study suggested that addition of Idarubicin to the MAC preparative regimens Was safe,effective and feasible for patients with acute myeloid leukemia,and may improve disease-free survival and overall survival.